If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-04. Numbers and descriptions here follow the published literature rather than marketing material.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Thymidine kinase is one of the many nucleoside kinases that are responsible for nucleoside phosphorylation. It phosphorylates thymidine to create thymidine monophosphate (dTMP). This kinase uses an ATP molecule to supply the phosphate to thymidine, as shown below. This transfer of a phosphate from one nucleotide to another by thymidine kinase, as well as other nucleoside and nucleotide kinases, functions to help control the level of each of the different nucleotides.
Aerotolerant anaerobes use fermentation to produce ATP. They do not use oxygen, but they can protect themselves from reactive oxygen molecules. In contrast, obligate anaerobes can be harmed by reactive oxygen molecules. There are three categories of anaerobes. Where obligate aerobes require oxygen to grow, obligate anaerobes are damaged by oxygen, aerotolerant organisms cannot use oxygen but tolerate its presence, and facultative anaerobes use oxygen if it is present but can grow without it. Most aerotolerant anaerobes have superoxide dismutase and (non-catalase) peroxidase but do not have catalase. More specifically, they may use a NADH oxidase/NADH peroxidase (NOX/NPR) system or a glutathione peroxidase system. An example of an aerotolerant anaerobe is Cutibacterium acnes.
=== Rhodium === It is possible to extract rhodium from used nuclear fuel: 1 kg of fission products of 235U contains 13.3 grams of 103Rh. At 3% fission products by weight, one ton of used fuel will contain about 400 grams of rhodium. The longest lived radioisotope of rhodium is 102mRh with a half-life of 2.9 years, while the ground state (102Rh) has a half-life of 207 days. Each kilogram of fission rhodium will contain 6.62 ng of 102Rh and 3.68 ng of 102mRh. As 102Rh decays by beta decay to either 102Ru (80%) (some positron emission will occur) or 102Pd (20%) (some gamma ray photons with about 500 keV are generated) and the excited state decays by beta decay (electron capture) to 102Ru (some gamma ray photons with about 1 MeV are generated). If the fission occurs in an instant then 13.3 grams of rhodium will contain 67.1 MBq (1.81 mCi) of 102Rh and 10.8 MBq (291 μCi) of 102mRh. As it is normal to allow used nuclear fuel to stand for about five years before reprocessing, much of this activity will decay away leaving 4.7 MBq of 102Rh and 5.0 MBq of 102mRh. If the rhodium metal was then left for 20 years after fission, the 13.3 grams of rhodium metal would contain 1.3 kBq of 102Rh and 500 kBq of 102mRh. Rhodium has the highest price of these precious metals ($440,000/kg in 2022), but the cost of the separation of the rhodium from the other metals needs to be considered, although recent high prices may create opportunity for consideration.
Sources: en.wikipedia.org
Definition of a chemical model of the equilibria. The model consists of a list of reagents, A, B, etc. and the complexes formed from them, with stoichiometries ApBq... Known or estimated values of the equilibrium constants for the formation of all complexes must be supplied. Calculation of the concentrations of all the chemical species in each solution. The free concentrations are calculated by solving the equations of mass-balance, and the concentrations of the complexes are calculated using the equilibrium constant definitions. A quantity corresponding to the observed quantity can then be calculated using physical principles such as the Nernst potential or Beer-Lambert law which relate the calculated quantity to the concentrations of the species. Refinement of the equilibrium constants. Usually a Non-linear least squares procedure is used. A weighted sum of squares, U, is minimized.
== Health effects == Supplementation with vitamin D is a reliable method for preventing or treating rickets. On the other hand, the effects of vitamin D supplementation on non-skeletal health are uncertain. A review did not find any effect from supplementation on the rates of non-skeletal disease, other than a tentative decrease in mortality in the elderly. Vitamin D supplements do not alter the outcomes for myocardial infarction, stroke or cerebrovascular disease, cancer, bone fractures or knee osteoarthritis. A US Institute of Medicine (IOM) report states: "Outcomes related to cancer, cardiovascular disease and hypertension, and diabetes and metabolic syndrome, falls and physical performance, immune functioning and autoimmune disorders, infections, neuropsychological functioning, and preeclampsia could not be linked reliably with intake of either calcium or vitamin D, and were often conflicting." Evidence for and against each disease state is provided in detail. Some researchers claim the IOM was too definitive in its recommendations and made a mathematical mistake when calculating the blood level of vitamin D associated with bone health. Members of the IOM panel maintain that they used a "standard procedure for dietary recommendations" and that the report is solidly based on the data.
In January 2025, President Donald Trump signed an executive order demanding that various drug cartels and criminal organizations (Sinaloa Cartel, Gulf Cartel, La Nueva Familia Michoacana, Jalisco New Generation Cartel, Northeast Cartel, United Cartels, Tren de Aragua and Mara Salvatrucha) be added to the list of Foreign Terrorist Organizations and Specially Designated Global Terrorists, which was officially enacted on 20 February, 2025, making such groups officially Foreign Terrorist Organizations. Similarly, Canada has also joined in designating drug cartels as Foreign Terrorist Organizations. Also, in the same year, the United States similarly designated and added the Los Lobos and Los Choneros gangs to the list of foreign terrorist organizations. On October 1, 2025, in the context of Operation Southern Spear and the US naval deployment in the Caribbean, President Donald Trump formally declared that the US is engaged in a "non-international armed conflict" with "unlawful combatants" associated with drug cartels operating in the Caribbean. This legal shift enabled operations such as the recent Operation Absolute Resolve on January 3, 2026, in which US special forces captured former Venezuelan leader Nicolás Maduro in Caracas on charges of narco-terrorism.
Sources: en.wikipedia.org
=== Pharmacodynamics === Enobosarm is a selective androgen receptor modulator (SARM), or a tissue-selective mixed agonist or partial agonist of the androgen receptor (AR). This receptor is the biological target of endogenous androgens like testosterone and dihydrotestosterone (DHT) and of synthetic anabolic steroids like nandrolone and oxandrolone. The affinity (Ki) of enobosarm for the AR is high and was measured as 3.8 nM in one study, or approximately 16.8% of that of DHT. Enobosarm shows enantioselectivity for the AR and has similar but somewhat lower potency than DHT in terms of activating the receptor. In addition to general activation of the AR, enobosarm induces the N/C interaction (the interaction of the amino terminus and carboxyl terminus) of the AR less potently than does DHT, but in any case promotes the N/C interaction concentration-dependently and to the same maximal extent as DHT. The AR is widely expressed in tissues throughout the body, including in the prostate gland, seminal vesicles, genitals, gonads, skin, hair follicles, muscle, bone, heart, adrenal cortex, liver, kidneys, and brain, among others. The effects of SARMs including enobosarm in many of these tissues have yet to be characterized.
== Comparison of somatostatin receptor agonists and antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had a higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time, and unbound more slowly than the Lu-DOTA-TATE agonist.
=== Post-operative complication === OSA can also occur as a serious post-operative complication that seems to be most frequently associated with pharyngeal flap surgery as compared to other procedures for the treatment of velopharyngeal inadequacy (VPI). In OSA, recurrent interruptions of respiration during sleep are associated with temporary airway obstruction. Following pharyngeal flap surgery, depending on size and position, the flap itself may have an "obturator" or obstructive effect within the pharynx during sleep, blocking ports of airflow and hindering effective respiration. There have been documented instances of severe airway obstruction, and reports of post-operative OSA continues to increase as healthcare professionals (i.e. physicians, speech language pathologists) become more educated about this possible dangerous condition. Subsequently, in clinical practice, concerns of OSA have matched or exceeded interest in speech outcomes following pharyngeal flap surgery. The surgical treatment for velopalatal insufficiency may cause obstructive sleep apnea syndrome. When velopalatal insufficiency is present, air leaks into the nasopharynx even when the soft palate should close off the nose. A simple test for this condition can be made by placing a tiny mirror on the nose and asking the subject to say "P". This p sound, a plosive, is normally produced with the nasal airway closed off – all air comes out of the pursed lips, none from the nose.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.